192725-92-1

Upstream product

• 192725-91-0 N⁽¹⁾-t-butyloxycarbonyl-N⁽²⁾-formylmethyl-N⁽²⁾-benzyloxycarbonyl hydrazine 
• 501-53-1 benzyl chloroformate 
• 937276-28-3 N^β-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-N^β-(2-hydroxyethyl)hydrazide 
• 316802-29-6 N^β-(benzyloxycarbonyl)-N^β-(2-hydroxyethyl)hydrazide 

Downstream Products

• 937276-25-0 methyl N-[2-(N^β-benzyloxycarbonyl-N^α-tert-butoxycarbonyl-hydrazino)ethyl]glycinate 
• 937276-21-6 methyl N-[2-(N^β-benzyloxycarbonyl-N^α-tert-butoxycarbonyl-hydrazino)ethyl]-N-[(thymin-1-yl)acetyl]glycinate 
• 937276-22-7 methyl N-[2-(N^β-benzyloxycarbonyl-N^α-tert-butoxycarbonylhydrazino)ethyl]-N-{[4-N-(benzyloxycarbonyl)cytosin-1-yl]acetyl}glycinate 

Relevant academic research and scientific papers

Synthesis of hydrazino-peptide nucleic acid monomers and dimers as new PNA backbone building blocks

We describe the synthesis of new hydrazinoPNA (hydPNA) monomers and new hydPNA-containing dimers. For the hydPNA monomers, the primary terminal amino group of the aminoethylglycine unit of classical aegPNA is replaced by a hydrazine moiety. An appropriate

Retroviral protease inhibiting compounds

A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A compound of the formula: STR1 is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.